Article
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
The Lancet
(2017)
Disciplines
Publication Date
January 6, 2017
DOI
10.1016/S0140-6736(17)31429-0
Citation Information
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, et al.. "Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial" The Lancet Vol. 389 Iss. 10086 (2017) p. 2317 - 2327 Available at: http://works.bepress.com/philip-mease/78/